SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999;33:3955.
  • 2
    Heaney DC, Sander JWAS. Ensuring appropriate care in epilepsy: an overview of epidemiological and cost of illness considerations. Dis Manage Health Outcomes 1998;4:30313.
  • 3
    Johnson WF, Newer MR. Cost of treating patients. In: EngelJ, PedleyTA, eds.) Epilepsy: A comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:2893900.
  • 4
    Cockerell OC. The economic cost of epilepsy. In: ShorvonS, DreifussF, FishD, ThomasD, eds. The treatment of epilepsy. London: Blackwell Science, 1996.
  • 5
    Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Quart 1982;60:42961.
  • 6
    Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:5926.
  • 7
    Begley CE, Famulari A, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based and survey data. Epilepsia 2000;41:34252.
  • 8
    Cockerell OC, Johnson AL, Sander JWAS, et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997;38:3146.
  • 9
    Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:72937.
  • 10
    Begley CE, Annegers JF, Lairson DR, et al. Costs of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994;35:123043.
  • 11
    Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998;39(suppl 3): S1925.
  • 12
    Reinharz D, Kennedy W, Contandriopoulos AP, et al. The economic effects of introducing vigabatrin, a new antiepileptic medication. Pharmacoeconomics 1995;8:4009.
  • 13
    Famulari M. The effects of a disability on labor market performance: the case of epilepsy. South Econ J 1992;58:107287.
  • 14
    Tomson T. Mortality in epilepsy. J Neurol 2000;247:1521.
  • 15
    Koopmanschap MA, Rutten FFH, Van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:17189.
  • 16
    Burke TA, McKee JR, Pathak DS, et al. Costs of epilepsy in an intermediate care facility for persons with mental retardation. Am J Ment Retard 1999;104:14857.
  • 17
    Schlienger RG, Oh PI, Knowles SR, et al. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998;39(suppl 7):S2732.
  • 18
    Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996;5:8995.
  • 19
    Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998;51:102633.
  • 20
    Griffiths RI, Schrammel PN, Morris GL, et al. Payer costs of patients diagnosed with epilepsy. Epilepsia 1999;40:3518.
  • 21
    O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: The Cooperative Cardiovascular Project. JAMA 1999;17: 627-33.
  • 22
    Park RE, Brook RH, Kosecoff J, et al. Explaining variations in hospital death rates: randomness, severity of illness, quality of care. JAMA 1990;264:48490.
  • 23
    Tetto A, Manzoni P, Millul A, et al. A prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002;48:20716.
  • 24
    Guerrini R, Battini R, Ferrari AR, et al., and the Epilepsy Collaborative Study Group. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia 2001;42:6416.
  • 25
    Cockerell OC, Hart YM, Sander JWAS, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994;18:24960.
  • 26
    Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998;39:77686.
  • 27
    Van Hout B, Gagnon D, Souetre E, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and United Kingdom. Epilepsia 1997;38:12216.
  • 28
    De Zelicourt M, Buteau L, Fagnani F, et al. The contributng factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagosed epileptic seizures (the CAROLE study). Seizure 2000;9:8895.
  • 29
    Heaney DC, Sander JWAS, Shorvon SD. Comparing the cost of epilepsy across eight European countries. Epilepsy Res 2001;43:8995.